Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

Phase I trial to study the effectiveness of combining erlotinib and trastuzumab with paclitaxel in treating patients who have advanced solid tumors. Biological therapies such as erlotinib may interfere with the growth of the tumor cells and slow the growth of the tumor. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib and trastuzumab with paclitaxel may kill more tumor cells

Key facts

Study ID

NCT00042809

Run by

National Cancer Institute (NCI)

People needed

40

Starts

2002-05-01

Last updated by the study team

2013-01-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed metastatic solid tumor for which there are no effective standard treatment options
• HER2 positive (1+ to 3+)
• Tumor has a high likelihood of expressing epidermal growth factor receptor (EGFR)
• No evidence of leptomeningeal disease or brain metastases unless previously treated, currently asymptomatic, and off both antiepileptics and dexamethasone
• Patients with treated brain metastases are eligible if they are without any clinical change in their brain disease status for at least 4 weeks after whole brain irradiation
• Performance status - ECOG 0-2
• Performance status - Karnofsky 60-100%
• At least 12 weeks
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Bilirubin normal
• AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver has tumor involvement)
• Creatinine normal
• Creatinine clearance at least 60 mL/min
• LVEF more than 50% by radionuclide ventriculogram or MUGA scan
• No significant cardiovascular disease
• No prior congestive heart failure requiring therapy
• No unstable angina pectoris
• No myocardial infarction within the past 6 months
• No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
• Patients who are unable to swallow tablets and/or who have silicon-based G-tubes may dissolve the tablets in distilled water
• No active peptic ulcer disease
• HIV negative
• Not pregnant or nursing
• Negative pregnancy test

Where it is running

• Cancer Therapy and Research Center at The UT Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.